SymphonyAI companies are market-leading B2B AI companies transforming the enterprise with a new generation of AI solutions in retail and CPG, healthcare and life sciences, financial services, industrial manufacturing, energy, oil & gas, defense, and media and entertainment.
We are looking forward to expanding our collaboration with ConcertAI and exploring the application of analytics to RWD (real-world data) for generating RWE (real-world evidence) in genitourinary cancers, a key area of our oncology strategy
AI technology can help with compliance because it has the ability “to do things human beings are not typically good at like high frequency high volume data problems” or augment human capabilities. It’s a win-win. We reduce risks and it costs less money.
We are delighted to engage with Ayasdi on this mission-critical task of creating clinical pathways for our patient population. Our ability to rapidly construct clinical pathways based on our own data and measure adherence by our staff to those standards provides us with the opportunity to deliver better care at a lower cost to our patients. Given the complexity of the challenge, using AI to solve this problem is the right approach, and Ayasdi’s CVM application makes it accessible to our practitioners, a key part of the value proposition given Flagler does not have dedicated data science resources.
We consider supply chain efficiency and high-quality demand forecasting to be critical in driving customer satisfaction and ensuring that the right products are available at the right time, at the most affordable price. We have an extensive and growing retail operation that will benefit from Symphony RetailAI’s cutting-edge technologies and global best practices.
Precision Health Informatics’ model uses information from the molecular profile representing the genetics of the patient’s disease combined with the clinical information specific to that patient to develop personalized medicine solutions that are integral to diagnosing cancer and offering physicians and patients effective treatment options. ConcertAI’s leadership in solutions for precision medicine will help us derive more meaningful insights from patient data, that in turn may help us connect patients with appropriate clinical trials.